Stay Informed

Sign up for news & alerts

Already signed up?
Login here
What Can I Do?


Get Help
Need alcohol or drug help for yourself or someone else? GET HELP
Continuing Education
Free online courses for addiction counselors LEARN ONLINE
Resources
Resources
Find useful publications, online documents & more.


DrugScreening.org


 

Firm Seeks OK for Cannabis-Based MS Drug
September 7, 2006

Share Share Email
Email
Print
Print
SubscribeSubscribe
News Summary

GW Pharma has filed in Great Britain for approval of the cannabis-based drug Sativex, developed for treatment of muscle stiffness related to multiple sclerosis, the Daily Telegraph reported Sept. 6.

Sativex has already been approved for use in Canada, but not in the U.S.; it could become the first marijuana-based medicine in the U.K. Great Britain's MS Society said that a "very significant number" of MS patients would benefit from the drug, noting that many already are using marijuana purchased on the street to alleviate their symptoms.

GW Pharma officials were optimistic that the drug would be approved for sale in the U.K. within the next 12-15 months. ''We have a sizable body of positive clinical data to support the efficacy and safety of Sativex in MS spasticity," said GW's Stephen Wright. 

COMMENTS ON THIS ARTICLE:

Your Turn! Post a public comment (read guidelines):

Name:

Comment:
(limit 200
words)

Enter this word
(help):
Change

GUIDELINES: 
To keep this feature useful for all, please:

  1. Keep it clean, courteous, and on-topic. Comments are meant for thoughtful discussion of the article published above.

  2. Do not post promotional links to organizations, products or services, or personal requests for assistance (get help).

  3. Proof your comments carefully, use good spelling and punctuation, and don't use ALL CAPS. Comments are published immediately and cannot be edited.

Deceptive, slanderous and commercially-motivated posts are prohibited. We reserve the right to remove comments not conforming to these guidelines. (Report a comment).

Have questions or feedback? Contact us.